DermTech, Inc. (DMTK)
Stock Price:
$12.00 USD
-0.23 (-1.88%)
Updated Oct 28, 2020 2:01 PM EDT - Market open
Key Info
| Market Cap |
234.01M |
| Revenue (ttm) |
4.56M |
| Net Income (ttm) |
-27.26M |
| Shares Out |
19.50M |
| EPS (ttm) |
-3.34 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 28, 2020 |
| Last Price |
$12.00 |
| Previous Close |
$12.23 |
| Change ($) |
-0.23 |
| Change (%) |
-1.88% |
| Day's Open |
12.13 |
| Day's Range |
11.55 - 12.20 |
| Day's Volume |
44,965 |
| 52-Week Range |
6.09 - 16.95 |
More Stats
| Market Cap |
234.01M |
| Enterprise Value |
172.91M |
| Earnings Date (est) |
Nov 10, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
19.50M |
| Float |
13.95M |
| EPS (basic) |
-1.99 |
| EPS (diluted) |
-3.34 |
| FCF / Share |
-2.04 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
320,980 |
| Short Ratio |
2.57 |
| Short % of Float |
2.30% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
51.38 |
| PB Ratio |
4.30 |
| Revenue |
4.56M |
| Operating Income |
-27.70M |
| Net Income |
-27.26M |
| Free Cash Flow |
-32.89M |
| Net Cash |
61.10M |
| Net Cash / Share |
3.13 |
| Gross Margin |
1.32% |
| Operating Margin |
-608.17% |
| Profit Margin |
-598.40% |
| FCF Margin |
-722.04% |
| ROA |
-51.23% |
| ROE |
-120.52% |
| ROIC |
1,210.00% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (3)
| Buy |
3 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$21.33*
(77.75% upside)
Low
20.0
Current: $12.00
High
24.0
Target: 21.33
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2016 |
|---|
| Revenue | 3.36 | 2.44 | - |
| Revenue Growth | 37.76% | - | - |
| Gross Profit | 0.06 | -0.19 | - |
| Operating Income | -17.61 | -8.56 | - |
| Net Income | -19.69 | -10.00 | - |
| Shares Outstanding | 7.01 | 4.41 | 3.75 |
| Earnings Per Share | -2.81 | -2.27 | - |
| Operating Cash Flow | -17.79 | -7.61 | - |
| Capital Expenditures | -0.21 | -0.01 | - |
| Free Cash Flow | -18.00 | -7.62 | - |
| Cash & Equivalents | 15.37 | 4.75 | 0.03 |
| Total Debt | - | 5.54 | 0.17 |
| Net Cash / Debt | 15.37 | -0.78 | -0.14 |
| Assets | 18.21 | 5.66 | 0.19 |
| Liabilities | 5.72 | 11.02 | 0.17 |
| Book Value | 12.49 | -5.36 | 0.02 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
DermTech, Inc. |
| Country |
United States |
| Employees |
60 |
| CEO |
John D. Dobak |
Stock Information
| Ticker Symbol |
DMTK |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Diagnostics & Research |
| Unique Identifier |
NASDAQ: DMTK |
Description
DermTech, a molecular diagnostic company, develops and markets novel non-invasive diagnostic tests to diagnosis skin cancer and related conditions in the United States. The company offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. It also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. The company is also developing non-melanoma skin cancer diagnostic and non-melanoma skin cancer risk assessment products. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.